Group items tagged

The primary purpose of the AHRQ Mentored Research Scientist Career Development Awards (K01) program is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's health services research needs. This AHRQ program provides support and protected time to individuals with a research doctoral degree for an intensive, supervised research career development experience in health services research. The K01 award can be used both by individuals who propose to newly embark in heath services research training and those who had a hiatus in their research careers because of illness or family circumstances.

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

To fund technical studies to improve existing methods for detecting and controlling key housing-related health and safety hazards; to develop new methods to detect and control these hazards; and to improve our knowledge of these key housing-related health and safety hazards.

The End TB Strategy envisions a world free of tuberculosis (TB)-zero deaths, disease and suffering due to TB by 2035. This requires reducing the global TB incidence from >1250 cases per million people to <100 cases per million people within the next two decades. Each year, an estimated 10 million people develop TB disease, and an estimated 1.6 million TB people die from TB - the leading cause of death from any infectious disease. In 2017, 90% of all estimated new TB cases were adults (15 years of age or older), and 9% were persons living with HIV (PLHIV) with 72% living in Africa. Despite being preventable and treatable, large gaps in detection and treatment of TB cases remain; of the estimated 10 million new TB cases in 2017, only 6.4 million TB cases were officially reported.

The United States Government represented by the United States Agency for International Development in Ethiopia (USAID/Ethiopia) is seeking applications from qualified entities to implement the Eliminate Tuberculosis from Ethiopia (ETBE) Activity through a five-year Cooperative Agreement mechanism. Eligibility for this award is not restricted.

Applications must articulate how results will lead to a clinical impact for Veterans with GWI even if a clinical impact is not an immediate outcome. All applications must focus on features of GWI and Veterans of the 1990-1991 Gulf War affected by GWI. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project's potential impact on GWI. The types of activities supported include, but are not limited to, expansion of limited data on candidate markers, mechanistic targets; therapeutics and interventions; validation and advanced research on druggable mechanistic targets, identification and development of leading compounds, and collection of preclinical data for repurposing an existing approved drug or for new Investigational New Drug (IND) application submissions to the U.S. Food and Drug Administration (FDA). Applicants proposing to test FDA-approved drugs in animal models for efficacy must explain why preclinical testing is required prior to clinical pilot trials in humans

The FY19 GWIRP New Investigator Award supports investigators new to the field of GWI research at different stages of career development. This award enables such investigators to compete for funding separately from investigators with established programs of GWI research. The New Investigator Award aligns to the Discovery or Qualification phase as outlined in Section II.A.2. Previous experience in GWI research is allowed, but not required. However, applications naming a Principal Investigator (PI) with limited background in GWI research are strongly encouraged to include collaboration with investigators who are experienced in GWI research and/or possess other relevant expertise to strengthen the application. The application should describe how the collaboration(s) will augment the PI's ability to address the research question.

The intent of the FY19 PRARP InCASA is to support innovative research that improves the quality of life and care for individuals living with the common symptoms of TBI and/or AD/ADRD and/or their families and care providers, as related to the PRARP's mission (see Section II.A, Program Description). The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the contexts of the PRARP's mission and vision. This can include innovations and research for symptom reduction (e.g., cognitive, behavioral, function, mood), resiliency factors, increasing or maintaining independence, and support for families and care providers. The research innovations for the FY19 PRARP InCASA are expected to benefit the military, Veteran, and civilian communities. FY19 PRARP InCASA applications should be Innovation- and Impact-based.

The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US. Also listed under R01.

This announcement provides funds to recipients to partner with health systems and individual primary care clinics to implement evidence-based interventions (EBIs) to increase colorectal cancer (CRC) screening uptake among applicant defined populations age 50-75 years that have CRC screening rates lower than the national, regional, or local rate. Recipients will: 1) establish partnerships with health systems and primary care clinics to implement at least two of four EBIs recommended in The Community Guide (client reminders; provider reminders, reduction of structural barriers, and provider assessment and feedback); 2) establish partnerships with organizations that provide expertise to support the implementation of EBIs in primary care clinics; 3) conduct a formal assessment of each clinics capacity/readiness to implement EBIs; 4) utilize the clinic assessment to select appropriate EBIs to implement; 5) provide resources to partner clinics to provide and support completion of follow-up colonoscopies after a positive or abnormal screening test; and 6) collect and submit high-quality clinic-level data including baseline and annual CRC screening rates.

The opioid epidemic has disrupted public safety and significantly increased the burden on state and local law enforcement, substance abuse treatment delivery systems, mental health systems, child welfare and foster care, and the juvenile justice and criminal justice systems. Through this program, OJJDP is helping states and communities develop a data-driven, coordinated response to opioid abuse-related challenges that impact youth and community safety. Funding under this program may be used to support programs and services to youth and families impacted by both opioids and other substance use disorders.

The purpose of the 2020 HD4A CFP is primarily to award data access at no cost from one of eight anticipated data providers to successful applicants. Most selected projects will not receive a financial award for personnel or other project-related costs. However, limited funding up to $100,000 per project is available for a small number of projects from principal investigators who have not previously received external research funding.

EPA's Office of Air and Radiation announces competitive funding announcements for projects and programs relating to air quality, transportation, climate change, indoor air and other related topics. EPA is soliciting applications from eligible entities to conduct demonstration, technical assistance, training, education, and/or outreach projects that seek to reduce exposure to indoor air contaminants by advancing national policy and systems-level initiatives. Applications should clearly articulate a plan to produce results that have implications and/or benefits on a national level. This RFA is not intended to fund small-scale local projects. Applications should also address one or more of the following EPA Indoor Air Program priority areas: Radon, Indoor Environmental Asthma Triggers, or Comprehensive Indoor Air Risk Reduction. EPA will not consider any applications under this RFA that are exclusively designed to conduct scientific research. However, applications may include research components as a foundation for demonstration, technical assistance, training, education, and/or outreach projects. Up to five awards of up to $200,000 will be distributed.

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

To support generation of single cell RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid, cocaine and/or methamphetamine use disorder

The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications proposing research that will address behavioral, technical and practical aspects of interventions and communication strategies to reduce exposures and/or health risks of wildland fire smoke.

The goal of the NOSI is to develop strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US. The NOSI will solicit research to help understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, human papilloma virus, pneumococcal, influenza, hepatitis B, and herpes zoster) that target adults in the United States and territories, especially among populations who are at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. The program will solicit community-engaged research to: 1) evaluate innovative interventions (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations.